NCT04126772Active, not recruiting
Multimodal Imaging of MS Reveals the Smoldering Inflammation
Source: ClinicalTrials.gov · Last updated 15 Jan 2025
Brief summary (registry, in English)
To evaluate active MS plaque evolution with conventional MRI, QSM-post processing, TSPO-PET imaging and P2X7-PET imaging.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 5 Aug 2019
- Start date
- 27 Feb 2019
- Primary completion date
- Dec 2025
- Lead sponsor
- Turku University Hospital
- Diseases
- Multiple sclerosis
- NCT number
- NCT04126772
What you commit to
- Study type: Observational
- Planned participants: 40
- From 27 Feb 2019 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Steroid treatment 4 weeks prior to the scan
- Steroid treatment 4 weeks prior to the scan or other regular medication
Other illness
- Patients suffering from another brain disease or other autoimmune disease in addition to multiple sclerosis
- Patients suffering from claustrophobia or panic disorder, or patients who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
- autoimmune disease, CNS disease or other serious disease
- persons suffering from claustrophobia or panic disorder, or persons who have exhibited hypersensitivity of PET markers (practical obstacle to the scan)
Age
- Age over 70
- Healthy controls:
- Age over 70
Other
- MS-patients:
- Significant pathology in the MRI scan other than MS-related lesions
- Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
- Exposure to experimental radioactivity in the last 12 months such that the dosimetry threshold would be exceeded due to participation in the study
Who the study is looking for
- Active MS-patients:
- Informed consent form
- At least one 0,5 cm diameter active gadolinium enhancing lesion detected lately
- Diagnosed MS-disease according to McDonald criteria
- SPMS patients
- Informed consent form
- Diagnosed MS-disease according to McDonald criteria
- SPMS disease
- Healthy controls:
- Informed consent form
- healthy
- age and sex matched with MS-patients in RRMS and SPMS groups
Age in the registry: 18 years to 70 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Turku PET Centre Coordinator of this site? Confirm its status | Turku | Finland | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.